Subcutaneously Administered CAMPATH in CD52 Expressing Hematologic Malignancies

Clinical trial NCT00113048 · TERMINATED

Trial details

NCT number: NCT00113048
Sponsor: Genzyme, a Sanofi Company
Status: TERMINATED
Phase: Phase 1
Study type: INTERVENTIONAL

Hematologic Malignancies

Start date: 2003-12-01
Enrollment: 24

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.